Serum concentrations of Krebs von den Lungen-6 in different COVID-19 phenotypes.
作者信息
d'Alessandro Miriana, Cameli Paolo, Bergantini Laura, Franchi Federico, Scolletta Sabino, Bargagli Elena
机构信息
Respiratory Diseases and Lung Transplantation, Department of Medical and Surgical Sciences and Neurosciences, Siena University Hospital, Siena, Italy.
Department of Medicine, Surgery and Neuroscience, Anesthesia and Intensive Care Unit, University of Siena, Siena, Italy.
出版信息
J Med Virol. 2021 Feb;93(2):657. doi: 10.1002/jmv.26431. Epub 2020 Aug 25.
Abstract
摘要
相似文献
1
Serum concentrations of Krebs von den Lungen-6 in different COVID-19 phenotypes.不同新冠病毒疾病（COVID-19）表型中肺癌6号抗原（Krebs von den Lungen-6）的血清浓度
J Med Virol. 2021 Feb;93(2):657. doi: 10.1002/jmv.26431. Epub 2020 Aug 25.
2
Serum Krebs von den Lungen-6 levels are associated with mortality and severity in patients with coronavirus disease 2019.血清肺癌-6 水平与 2019 年冠状病毒病患者的死亡率和严重程度相关。
Respir Investig. 2021 Sep;59(5):596-601. doi: 10.1016/j.resinv.2021.04.002. Epub 2021 Apr 27.
3
Exploration and correlation analysis of changes in Krebs von den Lungen-6 levels in COVID-19 patients with different types in China.中国不同类型 COVID-19 患者中 Krebs von den Lungen-6 水平变化的探索和关联分析。
Biosci Trends. 2020 Sep 21;14(4):290-296. doi: 10.5582/bst.2020.03197. Epub 2020 Jun 21.
4
Krebs Von den Lungen-6 as a predictive indicator for the risk of secondary pulmonary fibrosis and its reversibility in COVID-19 patients.癌胚抗原6作为新冠病毒感染患者继发性肺纤维化风险及其可逆性的预测指标
Int J Biol Sci. 2021 Apr 10;17(6):1565-1573. doi: 10.7150/ijbs.58825. eCollection 2021.
5
Serum Krebs von den Lungen-6 for Predicting the Severity of COVID-19 Lung Injury: A Systematic Review and Meta-Analysis.血清肺癌标志物 6 预测 COVID-19 肺损伤严重程度的系统评价和荟萃分析。
Iran Biomed J. 2021 Nov 1;25(6):381-9. doi: 10.52547/ibj.25.6.381.
6
Krebs von den Lungen-6 as Disease Severity Marker for COVID-19 Patients: Analytical Verification and Quality Assessment of the Tosoh AIA-360 Compared to Lumipulse G600II.肺腺癌 6 作为 COVID-19 患者疾病严重程度标志物：Tosoh AIA-360 与 Lumipulse G600II 的分析验证和质量评估。
Int J Environ Res Public Health. 2022 Feb 15;19(4):2176. doi: 10.3390/ijerph19042176.
7
Krebs von den Lungen-6 levels at admission predicts exercise-induced hypoxemia before and after discharge in patients with COVID-19.入院时的肺癌 6 水平可预测 COVID-19 患者出院前后运动引起的低氧血症。
Respir Investig. 2024 May;62(3):369-374. doi: 10.1016/j.resinv.2024.02.011. Epub 2024 Mar 1.
8
Plasma Krebs von den Lungen glycoprotein, lung injury, and noninvasive ventilation in Duchenne muscular dystrophy.血浆 Krebs von den Lungen 糖蛋白、肺损伤与杜氏肌营养不良症的无创通气。
Am J Phys Med Rehabil. 2012 Oct;91(10):831-5. doi: 10.1097/PHM.0b013e31825f1414.
9
Serum concentrations of Krebs von den Lungen-6, surfactant protein D, and matrix metalloproteinase-2 as diagnostic biomarkers in patients with asbestosis and silicosis: a case-control study.血清 Krebs von den Lungen-6、表面活性剂蛋白 D 和基质金属蛋白酶-2 浓度作为石棉肺和矽肺患者的诊断生物标志物：一项病例对照研究。
BMC Pulm Med. 2017 Nov 17;17(1):144. doi: 10.1186/s12890-017-0489-0.
10
Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.血清 Krebs von den Lungen-6 水平升高与系统性硬化症：肺纤维化和疾病严重程度的标志物。
Rheumatol Int. 2018 May;38(5):813-819. doi: 10.1007/s00296-018-3987-3. Epub 2018 Feb 17.
引用本文的文献
1
Eight-fold increased COVID-19 mortality in autosomal dominant tubulointerstitial kidney disease due to MUC1 mutations: an observational study.MUC1突变所致常染色体显性遗传性肾小管间质性肾病患者的新冠病毒疾病死亡率增加8倍：一项观察性研究
BMC Nephrol. 2024 Dec 18;25(1):449. doi: 10.1186/s12882-024-03896-1.
2
Cellular and molecular features of COVID-19 associated ARDS: therapeutic relevance.新冠病毒相关急性呼吸窘迫综合征的细胞和分子特征：治疗意义
J Inflamm (Lond). 2023 Mar 20;20(1):11. doi: 10.1186/s12950-023-00333-2.
3
Krebs von den Lungen-6 as Disease Severity Marker for COVID-19 Patients: Analytical Verification and Quality Assessment of the Tosoh AIA-360 Compared to Lumipulse G600II.肺腺癌 6 作为 COVID-19 患者疾病严重程度标志物：Tosoh AIA-360 与 Lumipulse G600II 的分析验证和质量评估。
Int J Environ Res Public Health. 2022 Feb 15;19(4):2176. doi: 10.3390/ijerph19042176.
4
Krebs von den Lungen-6 (KL-6) as a clinical marker for severe COVID-19: A systematic review and meta-analyses.肺腺癌标志物 6（KL-6）作为严重 COVID-19 的临床标志物：系统评价和荟萃分析。
Virology. 2022 Jan;566:106-113. doi: 10.1016/j.virol.2021.11.006. Epub 2021 Dec 4.
5
Correlation of Krebs von den Lungen-6 and fibronectin with pulmonary fibrosis in coronavirus disease 2019.新型冠状病毒肺炎中肺表面活性物质相关蛋白A和纤连蛋白与肺纤维化的相关性
Clin Chim Acta. 2021 Jun;517:48-53. doi: 10.1016/j.cca.2021.02.012. Epub 2021 Feb 22.
6
Serum Concentrations of KL-6 in Patients with IPF and Lung Cancer and Serial Measurements of KL-6 in IPF Patients Treated with Antifibrotic Therapy.特发性肺纤维化（IPF）合并肺癌患者血清中KL-6的浓度以及接受抗纤维化治疗的IPF患者血清KL-6的连续测量结果
Cancers (Basel). 2021 Feb 9;13(4):689. doi: 10.3390/cancers13040689.
7
Prognostic bioindicators in severe COVID-19 patients.严重 COVID-19 患者的预后生物标志物。
Cytokine. 2021 May;141:155455. doi: 10.1016/j.cyto.2021.155455. Epub 2021 Jan 28.
8
Serial KL-6 measurements in COVID-19 patients.COVID-19 患者的 KL-6 连续测量。
Intern Emerg Med. 2021 Sep;16(6):1541-1545. doi: 10.1007/s11739-020-02614-7. Epub 2021 Jan 16.
9
Peripheral biomarkers' panel for severe COVID-19 patients.重症 COVID-19 患者的外周生物标志物组
J Med Virol. 2021 Mar;93(3):1230-1232. doi: 10.1002/jmv.26577. Epub 2020 Oct 10.
本文引用的文献
1
Serum KL-6 can distinguish between different phenotypes of severe COVID-19.血清KL-6可以区分重症新型冠状病毒肺炎的不同表型。
J Med Virol. 2021 Jan;93(1):158-160. doi: 10.1002/jmv.26268. Epub 2020 Jul 19.
2
Serum KL-6 concentrations as a novel biomarker of severe COVID-19.血清 KL-6 浓度作为严重 COVID-19 的新型生物标志物。
J Med Virol. 2020 Oct;92(10):2216-2220. doi: 10.1002/jmv.26087. Epub 2020 Jun 9.
3
Nationwide system to centralize decisions around ECMO use for severe COVID-19 pneumonia in Japan (Special Correspondence).日本全国范围内集中决策使用体外膜肺氧合治疗重症新冠肺炎的系统（特别报道）
J Intensive Care. 2020 Apr 24;8:29. doi: 10.1186/s40560-020-00445-4. eCollection 2020.
4
Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease.血清 KL-6 水平反映了与结缔组织病相关的间质性肺病的严重程度。
Arthritis Res Ther. 2019 Feb 14;21(1):58. doi: 10.1186/s13075-019-1835-9.
Zotero 插件